According to Zacks, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. “
Several other equities research analysts have also recently weighed in on HRTX. Cowen and Company restated a buy rating on shares of Heron Therapeutics in a research report on Saturday, July 9th. Leerink Swann restated a buy rating and issued a $33.00 price objective on shares of Heron Therapeutics in a research report on Sunday, October 2nd. JMP Securities reiterated a buy rating on shares of Heron Therapeutics in a research report on Friday, September 9th. Brean Capital began coverage on shares of Heron Therapeutics in a research report on Tuesday, October 4th. They set a buy rating and a $41.00 price target for the company. Finally, Jefferies Group lowered their price target on shares of Heron Therapeutics from $46.00 to $40.00 and set a buy rating for the company in a research report on Monday, October 3rd. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $42.29.
Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 15.40 on Tuesday. The company has a 50 day moving average of $17.83 and a 200 day moving average of $18.80. Heron Therapeutics has a 12 month low of $14.75 and a 12 month high of $31.32.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.96) by $0.21. Equities analysts forecast that Heron Therapeutics will post ($4.39) earnings per share for the current year.
In other Heron Therapeutics news, insider Robert Rosen sold 100,000 shares of Heron Therapeutics stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $23.30, for a total value of $2,330,000.00. Following the transaction, the insider now owns 102,640 shares of the company’s stock, valued at $2,391,512. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 20.31% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Cormorant Asset Management LLC raised its stake in shares of Heron Therapeutics by 3.8% in the first quarter. Cormorant Asset Management LLC now owns 1,750,000 shares of the biotechnology company’s stock worth $33,233,000 after buying an additional 64,281 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Heron Therapeutics by 6.0% in the first quarter. JPMorgan Chase & Co. now owns 348,685 shares of the biotechnology company’s stock worth $6,622,000 after buying an additional 19,737 shares in the last quarter. VHCP Management II LLC acquired a new stake in shares of Heron Therapeutics during the first quarter worth approximately $7,708,000. California State Teachers Retirement System raised its stake in shares of Heron Therapeutics by 7.6% in the second quarter. California State Teachers Retirement System now owns 66,632 shares of the biotechnology company’s stock worth $1,203,000 after buying an additional 4,732 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Heron Therapeutics by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 147,986 shares of the biotechnology company’s stock worth $2,672,000 after buying an additional 4,579 shares in the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.